MBX Biosciences, Inc. Common Stock (MBX) Stock
NASDAQ · MBX
Key stats
- Market cap
- $2.87B
- Price / Earnings ratio
- -19.3x
- EPS (TTM)
- -$3.02
- Volume
- Loading
- 52-week high
- $72.64
- 52-week low
- $23.07
Source: third-party data provider, as of November 13, 2026
Compare with MBX
Recent news

MarketBeat
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
MBXMay 11, 2026
MarketBeat
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
MBX

The Motley Fool
MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know
MBXMarch 26, 2026
The Motley Fool
MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know
MBX

The Motley Fool
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
MBXDecember 3, 2025
The Motley Fool
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
MBX

Zacks Investment Research
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6%
MBXDecember 1, 2025
Zacks Investment Research
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6%
MBX
Technical indicators
- RSI 14
- 57.36
- MACD 12/26/9
- -0.15
- EMA 9 of MACD
- -0.88
- MACD histogram
- 0.73
- SMA 50
- $56.02
- Price above SMA 50
- EMA 50
- $55.26
- Price above EMA 50
- SMA 200
- $46.14
- Price above SMA 200
- EMA 200
- $46.24
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Strong Sell0
Sell0
Hold0
Buy3
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2022
2023
2024
2025
462M305M153M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-87.0M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

MarketBeat
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
MBXMay 11, 2026
MarketBeat
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
MBX

The Motley Fool
MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know
MBXMarch 26, 2026
The Motley Fool
MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know
MBX

The Motley Fool
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
MBXDecember 3, 2025
The Motley Fool
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
MBX

Zacks Investment Research
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6%
MBXDecember 1, 2025
Zacks Investment Research
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6%
MBX

Zacks Investment Research
Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus
MBXDecember 1, 2025
Zacks Investment Research
Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus
MBX
About MBX Biosciences, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees63
CEOMr. Steven L. Hoerter
IPO DateSep 12, 2024
HeadquartersCarmel, IN
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven L. Hoerter | Executive Chairperson, CEO & President | 1971 |
| Mr. John W. Smither CPA | Chief Financial Officer | 1953 |
| Dr. Salomon Azoulay M.D. | Chief Medical Officer | 1958 |
| Mr. Pete De Spain | Senior Vice President of Investor Relations & Corporate Communications | — |
| Ms. Michelle Graham | Chief Human Resources Officer | 1967 |
| Dr. Michael A. Dorato DABT, Ph.D. | Sr. Vice President of Discovery & Non-Clinical Development | — |
| Dr. Chatan Charan Ph.D. | Senior VP of Pharmaceutical Development & Chemistry, Manufacturing and Controls | — |
| Mr. Mark Hope | Senior Vice President of Regulatory & Quality | — |
| Dr. Andreas Moraitis M.D. | Senior Vice President of Clinical Development | — |
| Ms. Karen Basbaum M.B.A. | Chief Business Officer | — |
Fundamentals
Valuation
Price-to-book value5.91
Profitability
Return on Equity-34.00%
Return on Assets-33.00%
EBITDA$-144.42M
Trading
Average volume599,706
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 57.36
- MACD 12/26/9
- -0.15
- EMA 9 of MACD
- -0.88
- MACD histogram
- 0.73
- SMA 50
- $56.02
- Price above SMA 50
- EMA 50
- $55.26
- Price above EMA 50
- SMA 200
- $46.14
- Price above SMA 200
- EMA 200
- $46.24
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $84.00
- Average
- $107.33
- High
- $150.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | +9.9 | -4.8 | -9.4 | -3.0 | ||||||||
| 2025 | -45.2 | -8.5 | -27.2 | +52.9 | +10.1 | -13.2 | +14.1 | +9.7 | +20.1 | +22.7 | +67.3 | -4.4 |
| 2026 | +20.6 | -16.7 | -9.5 | -6.4 | +5.7 | +80.1 | +17.9 | -4.4 | -3.8 | -1.2 | +6.1 |
Compare stocks
Market cap
$2.87B
-
-
-
Price / Earnings ratio
-19.30
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
599,706
-
-
-
Earnings per share
$-3.02
-
-
-



